BioCentury on BioBusiness,
Product Discovery & Development
Hybridon abandons antisense trial
Monday, July 28, 1997
Hybridon Inc. on Friday said it has stopped development of its GEM91
phosphorothioate antisense oligonucleotide for treatment of HIV/AIDS, citing side effect
and efficacy problems it hopes will be overcome with second-generation compounds. HYBN was
down $1.625 Friday, closing the week at $3.125.
The decision came after HYBN's open label Phase II trial was halted
based on analysis of data from 9 of an expected 12 patients with advanced AIDS. The
patients had received 3.2 mg/kg/day of GEM91 by iv for 14 days. After 10 days of therapy,
3 of the 9 had to discontinue treatment when their platelet counts dropped below 50,000
Also, decreased levels of infectious virus seen in earlier trials were not observed in
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2016 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial Subscription 4 Weeks of Access
BioCentury's Weekly Business Intelligence Journal
Get a 4-week free trial subscription to BioCentury.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]